PTGS2 and colorectal carcinoma: Previous studies demonstrated that therapies targeting PGE2 by NSAIDs or COX-2 selective inhibitors were able to prevent CRC tumorigenesis, although severe cardiovascular side effects were observed in some patients [27,28].